Literature DB >> 16163158

Vascular endothelial growth factor receptors: expression and function in solid tumors.

Jane S Wey1, Oliver Stoeltzing, Lee M Ellis.   

Abstract

Vascular endothelial growth factor (VEGF) and its family members are important mediators of tumor angiogenesis. The multiple functions of the VEGF are mediated through complex and selective interactions between the ligands, their high-affinity tyrosine kinase receptors, and co-receptors (neuropilins). While these receptors are historically described as being exclusively expressed on endothelial cells, emerging evidence has documented expression of these receptors on a number of nonendothelial cells, including tumor cells. The VEGF receptors (VEGFR) have also been shown to be functional in a number of nonendothelial systems, where they may be targets for anti-VEGF therapy. This article will review the basic effects and interactions of the VEGFRs on endothelial cells and the evidence for their expression and function on tumor cells. The novel expression of VEGFRs on tumor cells contributes to the understanding of the complex roles of VEGF within the tumor microenvironment, potentially affecting both endothelial cells and tumor cells expressing the VEGFRs. This elucidation of VEGF activity may further refine antineoplastic regimens for solid malignancies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16163158

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  18 in total

Review 1.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

2.  Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma.

Authors:  B Zsebik; K Symonowicz; Y Saleh; P Ziolkowski; A Bronowicz; G Vereb
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

3.  VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density.

Authors:  Carla Ariotti; Vivian Petersen Wagner; Gabriela Salvadori; Vinicius Coelho Carrard; Marco Antônio Trevizani Martins; Joao Julio da Cunha Filho; Luise Meurer; Manoela Domingues Martins
Journal:  Tumour Biol       Date:  2015-04-21

4.  Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.

Authors:  Sirin A I Adham; Ifat Sher; Brenda L Coomber
Journal:  Lab Invest       Date:  2010-03-01       Impact factor: 5.662

5.  Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis.

Authors:  Xiao-Yong Man; Xiao-Hong Yang; Sui-Qing Cai; Yong-Gang Yao; Min Zheng
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

6.  Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Authors:  Grzegorz Korpanty; Laura A Sullivan; Elizabeth Smyth; Desmond N Carney; Rolf A Brekken
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

7.  Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

Authors:  M Pia Morelli; Amy M Brown; Todd M Pitts; John J Tentler; Fortunato Ciardiello; Anderson Ryan; Juliane M Jürgensmeier; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2009-09-15       Impact factor: 6.261

Review 8.  EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

Authors:  Michael F Press; Heinz-Josef Lenz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease.

Authors:  Thomas L Sims; Regan F Williams; Cathy Y Ng; Shannon F Rosati; Yunyu Spence; Andrew M Davidoff
Journal:  Surgery       Date:  2008-08       Impact factor: 3.982

10.  Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis.

Authors:  Stephen D Robinson; Louise E Reynolds; Vassiliki Kostourou; Andrew R Reynolds; Rita Graça da Silva; Bernardo Tavora; Marianne Baker; John F Marshall; Kairbaan M Hodivala-Dilke
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.